Sanofi (SNYNF) Cash from Financing Activities (2013 - 2026)
Sanofi's (SNYNF) quarterly Cash from Financing Activities came in at -$1.8 billion in Q1 2026, down 187.09% year-on-year from $2.1 billion in Q1 2025, and up 81.29% quarter-over-quarter from -$9.6 billion in Q4 2025.
Sanofi (SNYNF) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Sanofi has disclosed Cash from Financing Activities across 7 years of filings, most recently posting -$1.8 billion for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$1.8 billion, down 187.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.3 billion (down 234.57% YoY), and the FY2025 annual result was -$9.5 billion, down 54.22% from the prior year.
- Cash from Financing Activities came in at -$1.8 billion for Q1 2026 at Sanofi, up from -$9.6 billion in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $825.6 million in Q1 2024 to a low of -$9.6 billion in Q4 2025.
- The 3-year median for Cash from Financing Activities is -$3.1 billion (2026), against an average of -$3.6 billion.
- Peak annual rise in Cash from Financing Activities reached 55.13% in 2025, while the deepest fall reached 510.48% in 2025.
- Sanofi's Cash from Financing Activities stood at -$6.2 billion in 2024, then slumped by 55.13% to -$9.6 billion in 2025, then jumped by 81.29% to -$1.8 billion in 2026.
- The last three Cash from Financing Activities figures came in at -$1.8 billion (Q1 2026), -$9.6 billion (Q4 2025), and -$6.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 366.70 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | -1.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.79 Bn |
| Mar 31, 2026 | -1.79 Bn |
| Dec 31, 2025 | -9.55 Bn |
| Dec 31, 2025 | -9.55 Bn |
| Sep 30, 2025 | -6.59 Bn |
| Sep 30, 2025 | -6.59 Bn |
| Jun 30, 2025 | -4.41 Bn |
| Jun 30, 2025 | -4.41 Bn |
| Mar 31, 2025 | -622.72 Mn |
| Mar 31, 2025 | -622.72 Mn |
| Dec 31, 2024 | -6.16 Bn |
| Dec 31, 2024 | -6.16 Bn |
| Jun 30, 2024 | -722.59 Mn |
| Jun 30, 2024 | -722.59 Mn |
| Mar 31, 2024 | 825.63 Mn |
| Mar 31, 2024 | 825.63 Mn |
| Dec 31, 2021 | 30.32 Mn |
| Dec 31, 2021 | 30.32 Mn |
| Dec 31, 2020 | -10.02 Mn |
| Dec 31, 2020 | -10.02 Mn |